{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:49:47Z","timestamp":1760888987228},"reference-count":45,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1248\/bpb.b14-00769","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T17:06:40Z","timestamp":1425143200000},"page":"461-469","source":"Crossref","is-referenced-by-count":14,"title":["Liposomal Pemetrexed: Formulation, Characterization and &lt;i&gt;in Vitro&lt;\/i&gt; Cytotoxicity Studies for Effective Management of Malignant Pleural Mesothelioma"],"prefix":"10.1248","volume":"38","author":[{"given":"Noha","family":"Essam Eldin","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University"},{"name":"Department of Pharmacokinetics and Biopharmaceutics, Institute of Health Biosciences, The University of Tokushima"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan Mohamed","family":"Elnahas","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud Abd-Elghany","family":"Mahdy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Biopharmaceutics, Institute of Health Biosciences, The University of Tokushima"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Goudar RK. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma. <i>Ther. Clin. Risk Manag.<\/i>, <b>4<\/b>, 205\u2013211 (2008).","DOI":"10.2147\/TCRM.S1603"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Manegold C, Schmid-Bindert G, Pilz LR. Pemetrexed for the treatment of non-small-cell lung cancer. <i>Expert Rev. Anticancer Ther.<\/i>, <b>9<\/b>, 1195\u20131209 (2009).","DOI":"10.1586\/era.09.97"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Misset JL, Gamelin E, Campone M, Delaloge S, Latz JE, Bozec L, Fumoleau P. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. <i>Ann. Oncol.<\/i>, <b>15<\/b>, 1123\u20131129 (2004).","DOI":"10.1093\/annonc\/mdh279"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schultz RM. Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate. <i>Prog. Drug Res.<\/i>, <b>63<\/b>, 275\u2013300 (2005).","DOI":"10.1007\/3-7643-7414-4_11"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Adjei AA. Pharmacology and mechanism of action of pemetrexed. <i>Clin. Lung Cancer<\/i>, <b>5<\/b> (Suppl. 2), S51\u2013S55 (2004).","DOI":"10.3816\/CLC.2004.s.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jain RK. The next frontier of molecular medicine: delivery of therapeutics. <i>Nat. Med.<\/i>, <b>4<\/b>, 655\u2013657 (1998).","DOI":"10.1038\/nm0698-655"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, Brown EB, Izumi Y, Campbell RB, Berk DA, Jain RK. Role of tumor\u2013host interactions in interstitial diffusion of macromolecules: cranial <i>vs.<\/i> subcutaneous tumors. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>98<\/b>, 4628\u20134633 (2001).","DOI":"10.1073\/pnas.081626898"},{"key":"8","unstructured":"8) Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, Siccardi AG, Corti A. Tumor cell targeting with antibody\u2013avidin complexes and biotinylated tumor necrosis factor alpha. <i>Cancer Res.<\/i>, <b>57<\/b>, 1922\u20131928 (1997)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. <i>Cancer Res.<\/i>, <b>67<\/b>, 10958\u201310965 (2007).","DOI":"10.1158\/0008-5472.CAN-07-2233"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. <i>Nat. Nanotechnol.<\/i>, <b>2<\/b>, 751\u2013760 (2007).","DOI":"10.1038\/nnano.2007.387"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. <i>Br. J. Cancer<\/i>, <b>99<\/b>, 392\u2013397 (2008).","DOI":"10.1038\/sj.bjc.6604483"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. <i>Curr. Pharm. Des.<\/i>, <b>10<\/b>, 2981\u20132989 (2004).","DOI":"10.2174\/1381612043383467"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. <i>Anticancer Drugs<\/i>, <b>16<\/b>, 691\u2013707 (2005).","DOI":"10.1097\/01.cad.0000167902.53039.5a"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Juliano RL, Stamp D. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. <i>Biochem. Pharmacol.<\/i>, <b>27<\/b>, 21\u201327 (1978).","DOI":"10.1016\/0006-2952(78)90252-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Allen TM, Cheng WWK, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. <i>Anticancer. Agents Med. Chem.<\/i>, <b>6<\/b>, 513\u2013523 (2006).","DOI":"10.2174\/187152006778699121"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lasic DD, Papahadjopoulos D. Liposomes revisited. <i>Science<\/i>, <b>267<\/b>, 1275\u20131276 (1995).","DOI":"10.1126\/science.7871422"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. <i>Adv. Drug Deliv. Rev.<\/i>, <b>40<\/b>, 89\u2013102 (1999).","DOI":"10.1016\/S0169-409X(99)00042-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Chao TC, Wang WS, Yen CC, Chiou TJ, Liu JH, Chen PM. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. <i>Cancer Invest.<\/i>, <b>21<\/b>, 837\u2013847 (2003).","DOI":"10.1081\/CNV-120025086"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. <i>Methods Enzymol.<\/i>, <b>391<\/b>, 71\u201397 (2005).","DOI":"10.1016\/S0076-6879(05)91004-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Chen SE, Pace MB. Malignant pleural mesothelioma. <i>Am. J. Health Syst. Pharm.<\/i>, <b>69<\/b>, 377\u2013385 (2012).","DOI":"10.2146\/ajhp110281"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin <i>versus<\/i> cisplatin alone in patients with malignant pleural mesothelioma. <i>J. Clin. Oncol.<\/i>, <b>21<\/b>, 2636\u20132644 (2003).","DOI":"10.1200\/JCO.2003.11.136"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Richards DA, Loesch D, Vukelja SJ, Wu H, Hyman WJ, Nieves J, Wang Y, Hu S, Shonukan OO, Tai DF. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. <i>Invest. New Drugs<\/i>, <b>29<\/b>, 963\u2013970 (2011).","DOI":"10.1007\/s10637-010-9414-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Uemura T, Oguri T, Ozasa H, Takakuwa O, Miyazaki M, Maeno K, Sato S, Ueda R. ABCC11\/MRP8 confers pemetrexed resistance in lung cancer. <i>Cancer Sci.<\/i>, <b>101<\/b>, 2404\u20132410 (2010).","DOI":"10.1111\/j.1349-7006.2010.01690.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Litzinger DC, Huang L. Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications. <i>Biochim. Biophys. Acta<\/i>, <b>1113<\/b>, 201\u2013227 (1992).","DOI":"10.1016\/0304-4157(92)90039-D"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. <i>J. Control. Release<\/i>, <b>134<\/b>, 18\u201325 (2009).","DOI":"10.1016\/j.jconrel.2008.10.018"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Rouser G, Fleischer S, Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. <i>Lipids<\/i>, <b>5<\/b>, 494\u2013496 (1970).","DOI":"10.1007\/BF02531316"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. <i>Int. J. Pharm.<\/i>, <b>366<\/b>, 201\u2013210 (2009).","DOI":"10.1016\/j.ijpharm.2008.09.016"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. <i>Biochim. Biophys. Acta<\/i>, <b>1663<\/b>, 167\u2013177 (2004).","DOI":"10.1016\/j.bbamem.2004.03.006"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression <i>via<\/i> a dual-targeting approach in a murine solid tumor model. <i>J. Control. Release<\/i>, <b>137<\/b>, 8\u201314 (2009).","DOI":"10.1016\/j.jconrel.2009.02.023"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Jung MH, Yu J, Shin CH, Suh BK, Yang SW, Lee BC. Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms and HLA class II alleles with the development of type 1 diabetes in Korean children and adolescents. <i>J. Korean Med. Sci.<\/i>, <b>24<\/b>, 1004\u20131009 (2009).","DOI":"10.3346\/jkms.2009.24.6.1004"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Taylor KM, Roseman MA. Effect of cholesterol, fatty acyl chain composition, and bilayer curvature on the interaction of cytochrome <i>b<\/i>5 with liposomes of phosphatidylcholines. <i>Biochemistry<\/i>, <b>34<\/b>, 3841\u20133850 (1995).","DOI":"10.1021\/bi00011a042"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) McIntosh TJ. Differences in hydrocarbon chain tilt between hydrated phosphatidylethanolamine and phosphatidylcholine bilayers. A molecular packing model. <i>Biophys. J.<\/i>, <b>29<\/b>, 237\u2013245 (1980).","DOI":"10.1016\/S0006-3495(80)85128-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Liang X, Mao G, Ng KY. Mechanical properties and stability measurement of cholesterol-containing liposome on mica by atomic force microscopy. <i>J. Colloid Interface Sci.<\/i>, <b>278<\/b>, 53\u201362 (2004).","DOI":"10.1016\/j.jcis.2004.05.042"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. <i>Mol. Pharmacol.<\/i>, <b>62<\/b>, 864\u2013872 (2002).","DOI":"10.1124\/mol.62.4.864"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Chen J, Ping QN, Guo JX, Chu XZ, Song MM. Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. <i>Drug Dev. Ind. Pharm.<\/i>, <b>32<\/b>, 719\u2013726 (2006).","DOI":"10.1080\/03639040500529077"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Cagdas FM, Ertugral N, Bucak S, Atay NZ. Effect of preparation method and cholesterol on drug encapsulation studies by phospholipid liposomes. <i>Pharm. Dev. Technol.<\/i>, <b>16<\/b>, 408\u2013414 (2011).","DOI":"10.3109\/10837451003774401"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Alino SF, Garcia M, Lejarreta M, Bobadilla M, Perez-Yarza G, Unda FJ. Trapping drug efficiency in liposomes produced by extrusion of freeze-thaw multilamellar vesicles. <i>Biochem. Soc. Trans.<\/i>, <b>17<\/b>, 1000\u20131001 (1989).","DOI":"10.1042\/bst0171000"},{"key":"38","unstructured":"38) Chorachoo J, Amnuaikit T, Voravuthikunchai SP. Liposomal encapsulated rhodomyrtone: a novel antiacne drug. <i>Evid. Based Complement. Alternat. Med.<\/i>, <b>2013<\/b>, 157635 (2013)."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for <i>in vitro<\/i> transepidermal delivery targeting psoriasis treatment. <i>Int. J. Pharm.<\/i>, <b>427<\/b>, 426\u2013434 (2012).","DOI":"10.1016\/j.ijpharm.2012.01.045"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Anderson M, Omri A. The effect of different lipid components on the <i>in vitro<\/i> stability and release kinetics of liposome formulations. <i>Drug Deliv.<\/i>, <b>11<\/b>, 33\u201339 (2004).","DOI":"10.1080\/10717540490265243"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. <i>Clin. Cancer Res.<\/i>, <b>11<\/b>, 3567\u20133573 (2005).","DOI":"10.1158\/1078-0432.CCR-04-2517"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. <i>Biochim. Biophys. Acta<\/i>, <b>1023<\/b>, 133\u2013139 (1990).","DOI":"10.1016\/0005-2736(90)90018-J"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Katayama K, Kato Y, Onishi H, Nagai T, Machida Y. Preparation of novel double liposomes using the glass-filter method. <i>Int. J. Pharm.<\/i>, <b>248<\/b>, 93\u201399 (2002).","DOI":"10.1016\/S0378-5173(02)00427-1"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin <i>versus<\/i> doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma. <i>J. Clin. Oncol.<\/i>, <b>14<\/b>, 2353\u20132364 (1996).","DOI":"10.1200\/JCO.1996.14.8.2353"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. <i>Biochim. Biophys. Acta<\/i>, <b>1661<\/b>, 47\u201360 (2004).","DOI":"10.1016\/j.bbamem.2003.11.016"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/3\/38_b14-00769\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T07:57:43Z","timestamp":1566374263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/3\/38_b14-00769\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b14-00769","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}